Johnson & Johnson Operating Income 2006-2018 | JNJ

Current and historical operating income for Johnson & Johnson (JNJ) from 2006 to 2018. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted. Johnson & Johnson operating income for the twelve months ending June 30, 2018 was $17.804B. Johnson & Johnson operating income for the three months ending June 30, 2018 was $4.973B, representing a 4.74% increase from the same quarter last year.
Johnson & Johnson Annual Operating Income
(Millions of US $)
2017 $17,673
2016 $19,803
2015 $19,196
2014 $20,563
2013 $15,471
2012 $13,775
2011 $12,361
2010 $16,947
2009 $15,755
2008 $16,929
2007 $13,283
2006 $14,587
2005 $13,116
Johnson & Johnson Quarterly Operating Income
(Millions of US $)
Q2 2018 $4,973
Q1 2018 $5,481
Q4 2017 $2,560
Q3 2017 $4,790
Q2 2017 $4,748
Q1 2017 $5,575
Q4 2016 $4,324
Q3 2016 $5,281
Q2 2016 $4,904
Q1 2016 $5,294
Q4 2015 $3,758
Q3 2015 $4,122
Q2 2015 $5,741
Q1 2015 $5,575
Q4 2014 $2,703
Q3 2014 $6,810
Q2 2014 $5,626
Q1 2014 $5,424
Q4 2013 $2,750
Q3 2013 $3,667
Q2 2013 $4,793
Q1 2013 $4,261
Q4 2012 $3,100
Q3 2012 $3,595
Q2 2012 $2,035
Q1 2012 $5,045
Q4 2011 $318
Q3 2011 $4,111
Q2 2011 $3,422
Q1 2011 $4,510
Q4 2010 $2,228
Q3 2010 $4,219
Q2 2010 $4,220
Q1 2010 $6,280
Q4 2009 $2,604
Q3 2009 $4,245
Q2 2009 $4,263
Q1 2009 $4,643
Q4 2008 $3,517
Q3 2008 $4,290
Q2 2008 $4,375
Q1 2008 $4,747
Q4 2007 $2,332
Q3 2007 $3,268
Q2 2007 $4,031
Q1 2007 $3,652
Q4 2006 $2,708
Q3 2006 $3,661
Q2 2006 $3,603
Q1 2006 $4,615
Q4 2005 $2,503
Q3 2005 $3,420
Q2 2005 $3,266
Q1 2005 $3,927
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $350.789B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $243.651B 14.26
Novartis AG (NVS) Switzerland $190.263B 16.32
Merck (MRK) United States $178.137B 15.73
AbbVie (ABBV) United States $145.067B 14.17
Novo Nordisk (NVO) Denmark $114.528B 18.31
Eli Lilly (LLY) United States $109.815B 20.33
Sanofi (SNY) France $104.261B 13.20
AstraZeneca (AZN) United Kingdom $99.745B 10.97
GlaxoSmithKline (GSK) United Kingdom $99.569B 13.30
Bristol-Myers Squibb (BMY) United States $96.944B 17.55